and Validation of EP2-Receptor Agonism to Selectively Achieve Inhibition of Mast Cell Activity

Overview

Journal Allergy Asthma Immunol Res

Date 2020 May 14

PMID 32400135

Citations 6

Authors

Judith Plaza

Rosa Torres

Adrian Urbano

Cesar Picado

Fernando de Mora

Affiliations

Soon will be listed here.

Abstract

Purpose: Agonism of the prostaglandin E2 receptor, E-prostanoid receptor 2 (EP2), may represent an alternative protective mechanism in mast cell (MC)-mediated diseases. Previous studies have suggested that activation of the MC EP2 receptor prevents pathological changes in the murine models of allergic asthma. This work aimed to analytically validate the EP2 receptor on MCs as a therapeutic target.

Methods: Murine MC lines and primary cultures, and MCs bearing the human immunoglobulin E (IgE) receptor were subjected to IgE-mediated activation subsequent to incubation with selective EP2 agonists. Two molecularly unrelated agonists, butaprost and CP-533536, were tested either or in 2 models of allergy.

Results: The diverse range of MC populations was consistently inhibited through selective EP2 agonism in spite of exhibiting a heterogeneous phenotype. Such inhibition occurred in both mouse and human IgE (hIgE)-mediated activation. The use of molecularly unrelated selective EP2 agonists allowed for the confirmation of the specificity of this protective mechanism. This effect was further demonstrated in 2 murine models of allergy where MCs are a key to pathological changes: cutaneous anaphylaxis in a transgenic mouse model expressing the hIgE receptor and aeroallergen-induced murine model of asthma.

Conclusions: Selective EP2 agonism is a powerful pharmacological strategy to prevent MCs from being activated through IgE-mediated mechanisms and from causing deleterious effects. The MC EP2 receptor may be an effective pharmacological target in allergic and other MC-mediated conditions.

Citing Articles

Acetylsalicylic acid aggravates anaphylaxis in a PGE2-dependent manner.

Globig P, Morakabati P, Hofer V, Willmes D, Babina M, Worm M J Clin Invest. 2025; 135(5).

PMID: 40026245 PMC: 11870728. DOI: 10.1172/JCI175397.

Endogenous LXR signaling controls pulmonary surfactant homeostasis and prevents lung inflammation.

Hernandez-Hernandez I, de la Rosa J, Martin-Rodriguez P, Diaz-Sarmiento M, Recio C, Guerra B Cell Mol Life Sci. 2024; 81(1):287.

PMID: 38970705 PMC: 11335212. DOI: 10.1007/s00018-024-05310-3.

New Mechanistic Advances in FcεRI-Mast Cell-Mediated Allergic Signaling.

Li Y, Leung P, Gershwin M, Song J Clin Rev Allergy Immunol. 2022; 63(3):431-446.

PMID: 36251242 PMC: 9575623. DOI: 10.1007/s12016-022-08955-9.

Immunoglobulin E-Dependent Activation of Immune Cells in Rhinovirus-Induced Asthma Exacerbation.

Kawakami T, Kasakura K, Kawakami Y, Ando T Front Allergy. 2022; 3:835748.

PMID: 35386658 PMC: 8974681. DOI: 10.3389/falgy.2022.835748.

Emerging Role of Phospholipase-Derived Cleavage Products in Regulating Eosinophil Activity: Focus on Lysophospholipids, Polyunsaturated Fatty Acids and Eicosanoids.

Knuplez E, Sturm E, Marsche G Int J Mol Sci. 2021; 22(9).

PMID: 33919453 PMC: 8122506. DOI: 10.3390/ijms22094356.

References

Saitoh S, Arudchandran R, Manetz T, Zhang W, Sommers C, Love P . LAT is essential for Fc(epsilon)RI-mediated mast cell activation. Immunity. 2000; 12(5):525-35. DOI: 10.1016/s1074-7613(00)80204-6. View

Gomez G, Ramirez C, Rivera J, Patel M, Norozian F, Wright H . TGF-beta 1 inhibits mast cell Fc epsilon RI expression. J Immunol. 2005; 174(10):5987-93. PMC: 1391973. DOI: 10.4049/jimmunol.174.10.5987. View

Herrerias A, Torres R, Serra M, Marco A, Pujols L, Picado C . Activity of the cyclooxygenase 2-prostaglandin-E prostanoid receptor pathway in mice exposed to house dust mite aeroallergens, and impact of exogenous prostaglandin E2. J Inflamm (Lond). 2009; 6:30. PMC: 2776012. DOI: 10.1186/1476-9255-6-30. View

Wershil B, Mekori Y, Murakami T, Galli S . 125I-fibrin deposition in IgE-dependent immediate hypersensitivity reactions in mouse skin. Demonstration of the role of mast cells using genetically mast cell-deficient mice locally reconstituted with cultured mast cells. J Immunol. 1987; 139(8):2605-14. View

Torres R, Picado C, de Mora F . The PGE2-EP2-mast cell axis: an antiasthma mechanism. Mol Immunol. 2014; 63(1):61-8. DOI: 10.1016/j.molimm.2014.03.007. View

Torres R, Herrerias A, Serra-Pages M, Roca-Ferrer J, Pujols L, Marco A . An intranasal selective antisense oligonucleotide impairs lung cyclooxygenase-2 production and improves inflammation, but worsens airway function, in house dust mite sensitive mice. Respir Res. 2008; 9:72. PMC: 2600823. DOI: 10.1186/1465-9921-9-72. View

Nakamura R, Uchida Y, Higuchi M, Nakamura R, Tsuge I, Urisu A . A convenient and sensitive allergy test: IgE crosslinking-induced luciferase expression in cultured mast cells. Allergy. 2010; 65(10):1266-73. PMC: 3066406. DOI: 10.1111/j.1398-9995.2010.02363.x. View

Kirshenbaum A, Akin C, Wu Y, Rottem M, Goff J, Beaven M . Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. Leuk Res. 2003; 27(8):677-82. DOI: 10.1016/s0145-2126(02)00343-0. View

Li M, Ke H, Qi H, Healy D, Li Y, Crawford D . A novel, non-prostanoid EP2 receptor-selective prostaglandin E2 agonist stimulates local bone formation and enhances fracture healing. J Bone Miner Res. 2003; 18(11):2033-42. DOI: 10.1359/jbmr.2003.18.11.2033. View

10.

Nakata J, Kondo M, Tamaoki J, Takemiya T, Nohara M, Yamagata K . Augmentation of allergic inflammation in the airways of cyclooxygenase-2-deficient mice. Respirology. 2005; 10(2):149-56. DOI: 10.1111/j.1440-1843.2005.00687.x. View

11.

Chung K . Evaluation of selective prostaglandin E2 (PGE2) receptor agonists as therapeutic agents for the treatment of asthma. Sci STKE. 2005; 2005(303):pe47. DOI: 10.1126/stke.3032005pe47. View

12.

Torres R, Herrerias A, Serra-Pages M, Marco A, Plaza J, Costa-Farre C . Locally administered prostaglandin E2 prevents aeroallergen-induced airway sensitization in mice through immunomodulatory mechanisms. Pharmacol Res. 2013; 70(1):50-9. DOI: 10.1016/j.phrs.2012.12.008. View

13.

Duffy S, Cruse G, Cockerill S, Brightling C, Bradding P . Engagement of the EP2 prostanoid receptor closes the K+ channel KCa3.1 in human lung mast cells and attenuates their migration. Eur J Immunol. 2008; 38(9):2548-56. PMC: 2699428. DOI: 10.1002/eji.200738106. View

14.

Kay L, Yeo W, Peachell P . Prostaglandin E2 activates EP2 receptors to inhibit human lung mast cell degranulation. Br J Pharmacol. 2006; 147(7):707-13. PMC: 1751511. DOI: 10.1038/sj.bjp.0706664. View

15.

Torres R, Perez M, Marco A, Picado C, de Mora F . [A cyclooxygenase-2 selective inhibitor worsens respiratory function and enhances mast cell activity in ovalbumin-sensitized mice]. Arch Bronconeumol. 2009; 45(4):162-7. DOI: 10.1016/j.arbres.2008.04.007. View

16.

Roca-Ferrer J, Garcia-Garcia F, Pereda J, Perez-Gonzalez M, Pujols L, Alobid I . Reduced expression of COXs and production of prostaglandin E(2) in patients with nasal polyps with or without aspirin-intolerant asthma. J Allergy Clin Immunol. 2011; 128(1):66-72.e1. DOI: 10.1016/j.jaci.2011.01.065. View

17.

Brown J, Nemeth K, Kushnir-Sukhov N, Metcalfe D, Mezey E . Bone marrow stromal cells inhibit mast cell function via a COX2-dependent mechanism. Clin Exp Allergy. 2011; 41(4):526-34. PMC: 3078050. DOI: 10.1111/j.1365-2222.2010.03685.x. View

18.

Holgate S, Hardy C, Robinson C, Agius R, Howarth P . The mast cell as a primary effector cell in the pathogenesis of asthma. J Allergy Clin Immunol. 1986; 77(2):274-82. DOI: 10.1016/s0091-6749(86)80104-x. View

19.

Wang X, Lau H . Prostaglandin E potentiates the immunologically stimulated histamine release from human peripheral blood-derived mast cells through EP1/EP3 receptors. Allergy. 2006; 61(4):503-6. DOI: 10.1111/j.1398-9995.2006.01043.x. View

20.

Cameron K, Lefker B, Ke H, Li M, Zawistoski M, Tjoa C . Discovery of CP-533536: an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation. Bioorg Med Chem Lett. 2009; 19(7):2075-8. DOI: 10.1016/j.bmcl.2009.01.059. View